Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225216 | 0.95 | MTNR1A (0.45) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL3244852 | 0.93 | MTNR1A (0.44) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL7176162 | 0.90 | HPRT1 (0.45) | MTNR1ANQO2TDP1GPR84CA2 | |
| SCHEMBL143458 | 0.89 | MTNR1A (0.49) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL7176833 | 0.85 | HPRT1 (0.44) | MTNR1ANQO2TDP1GPR84MCL1 | |
| SCHEMBL9216856 | 0.85 | CYP1A2 (0.48) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL7190938 | 0.84 | MTNR1A (0.40) | MTNR1ANQO2GPR84CA2DAO | |
| SCHEMBL7184372 | 0.84 | HPRT1 (0.42) | MTNR1ANQO2TDP1GPR84MCL1 | |
| SCHEMBL9800436 | 0.82 | CYP1A2 (0.58) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL5830948 | 0.82 | GPR84 (0.59) | MTNR1ANQO2TDP1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 771 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375081-B2 | Therapeutic combination of a pneumocandin derivative and an antifungal agent | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | claimed |
| US-6875740-B1 | Combination of a cyclic hexapeptide with antifungal drugs for treatment of fungal pathogens | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-05 | — | — | US | claimed |
| EP-0966456-B1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2003-04-02 | — | — | EP | claimed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | claimed |
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | disclosed |
| US-20240034845-A1 | POLYMER PARTICLES | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2024-02-01 | — | — | US | disclosed |
| EP-3384549-B1 | SODIUM-ION ELECTROLYTE COMPOSITION | UNIV DEAKIN (AU) | 2024-01-17 | — | — | EP | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| US-20230348674-A1 | HYDROGELS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2023-11-02 | — | — | US | disclosed |
| WO-2023190111-A1 | RAFT POLYMERIZATION REACTION SOLUTION AND RAFT POLYMERIZATION REACTION SOLUTION PRODUCTION METHOD | テクノＵＭＧ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| WO-1992012154-A1 | IMIDAZOTRIAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-23 | — | — | WO | disclosed |
| WO-1992003438-A1 | TRICYCLIC BENZODIAZEPINE DERIVATES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-05 | — | — | WO | disclosed |
| WO-1992002513-A1 | HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-20 | — | — | WO | disclosed |
| US-4981847-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0360079-A1 | Tricyclic compounds, processes for their preparation and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-28 | — | — | EP | disclosed |
| EP-0336230-A2 | Cyclic peptide antagonists of Substance P and Substance K | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | MTNR1A 1398/4885NQO2 3834/4885TDP1 3735/4885 |
| US-20230348674-A1 | HYDROGELS | PHYKPL, TST, PHOSPHO1 | MTNR1A 4090/4885NQO2 2360/4885TDP1 2333/4885 |
| US-20240084308-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | MTNR1A 1398/4885NQO2 3834/4885TDP1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.